Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Breast 1
NL-OMON34674Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Afatinib + vinorelbine with Trastuzumab + vinorelbine (2 arms). Primary endpoint: Progression-free survival. Started Nov 2010; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON34674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34674.